| Stage | ABT | % of rev | MDT | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $13.0B | 100.00% | $9.8B | 100.00% | ABT ×1.33 |
| Gross profit | $7.4B | 56.75% | $6.3B | 64.99% | MDT +8.2pp |
| Operating income | $1.4B | 10.44% | $1.8B | 18.08% | MDT +7.6pp |
| Pre-tax income | $1.2B | 9.46% | $1.8B | 18.13% | MDT +8.7pp |
| Net income | $920M | 7.07% | $1.5B | 15.16% | MDT +8.1pp |
| Stage | ABT | MDT | Gap · A − B |
|---|---|---|---|
| Revenue | $13.0B100.00% | $9.8B100.00% | ABT ×1.33 |
| Gross profit | 56.75%$7.4B | 64.99%$6.3B | MDT +8.2pp |
| Operating income | 10.44%$1.4B | 18.08%$1.8B | MDT +7.6pp |
| Pre-tax income | 9.46%$1.2B | 18.13%$1.8B | MDT +8.7pp |
| Net income |
| 7.07%$920M |
| 15.16%$1.5B |
| MDT +8.1pp |
ABT · ITGR 10-KFeb 23 '26
“During 2025, three of our customers, Abbott Laboratories, Boston Scientific and Medtronic were each in excess of 10% of total sales and collectively accounted for 49% of our total sales.”
MDT · ITGR 10-KFeb 23 '26
“During 2025, three of our customers, Abbott Laboratories, Boston Scientific and Medtronic were each in excess of 10% of total sales and collectively accounted for 49% of our total sales.”